Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
09 08 2021
Historique:
received: 31 01 2021
accepted: 07 07 2021
entrez: 10 8 2021
pubmed: 11 8 2021
medline: 27 8 2021
Statut: epublish

Résumé

Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment. Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment. The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness. The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.

Sections du résumé

BACKGROUND
Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment.
METHODS
Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment.
RESULTS
The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness.
CONCLUSIONS
The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.

Identifiants

pubmed: 34372811
doi: 10.1186/s12888-021-03363-3
pii: 10.1186/s12888-021-03363-3
pmc: PMC8351147
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

392

Subventions

Organisme : FIC NIH HHS
ID : R03 TW006481
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH060220
Pays : United States

Investigateurs

Sergio Aguilar-Gaxiola (S)
Ali Al-Hamzawi (A)
Mohammed Salih Al-Kaisy (MS)
Jordi Alonso (J)
Yasmin A Altwaijri (YA)
Laura Helena Andrade (LH)
Lukoye Atwoli (L)
Corina Benjet (C)
Guilherme Borges (G)
Evelyn J Bromet (EJ)
Ronny Bruffaerts (R)
Brendan Bunting (B)
Jose Miguel Caldas-de-Almeida (JM)
Graça Cardoso (G)
Somnath Chatterji (S)
Alfredo H Cia (AH)
Louisa Degenhardt (L)
Koen Demyttenaere (K)
Silvia Florescu (S)
Giovanni de Girolamo (G)
Oye Gureje (O)
Josep Maria Haro (JM)
Meredith G Harris (MG)
Hristo Hinkov (H)
Chi-Yi Hu (CY)
Peter de Jonge (P)
Aimee Nasser Karam (AN)
Elie G Karam (EG)
Norito Kawakami (N)
Ronald C Kessler (RC)
Andrzej Kiejna (A)
Viviane Kovess-Masfety (V)
Sing Lee (S)
Jean-Pierre Lepine (JP)
John J McGrath (JJ)
Maria Elena Medina-Mora (ME)
Zeina Mneimneh (Z)
Jacek Moskalewicz (J)
Fernando Navarro-Mateu (F)
Marina Piazza (M)
Jose Posada-Villa (J)
Kate M Scott (KM)
Tim Slade (T)
Juan Carlos Stagnaro (JC)
Dan J Stein (DJ)
Margreet Ten Have (M)
Yolanda Torres (Y)
Maria Carmen Viana (MC)
Daniel V Vigo (DV)
Harvey Whiteford (H)
David R Williams (DR)
Bogdan Wojtyniak (B)

Informations de copyright

© 2021. The Author(s).

Références

Contemp Nurse. 2015 Oct-Dec;51(2-3):107-20
pubmed: 26866531
Br J Psychiatry. 2010 Nov;197(5):378-85
pubmed: 21037215
J Affect Disord. 2021 Jun 1;288:199-209
pubmed: 33940429
JAMA Psychiatry. 2020 Aug 1;77(8):830-841
pubmed: 32432716
Depress Anxiety. 2020 Oct;37(10):972-994
pubmed: 32667096
Psychol Med. 2011 Aug;41(8):1751-61
pubmed: 21134315
J Consult Clin Psychol. 1993 Dec;61(6):952-65
pubmed: 8113496
J Anxiety Disord. 2007;21(5):662-76
pubmed: 17118626
World Psychiatry. 2019 Oct;18(3):276-285
pubmed: 31496102
Arch Psychiatr Nurs. 2014 Feb;28(1):43-9
pubmed: 24506986
Cogn Behav Ther. 2020 Jan;49(1):1-21
pubmed: 30760112
Int J Psychiatry Clin Pract. 2006;10 Suppl 1:16-21
pubmed: 24931539
JAMA Psychiatry. 2017 May 1;74(5):465-475
pubmed: 28297020
JAMA Psychiatry. 2020 Aug 1;77(8):784-786
pubmed: 32432693
Front Behav Neurosci. 2014 Apr 24;8:131
pubmed: 24795583
Int Clin Psychopharmacol. 2011 Mar;26(2):75-83
pubmed: 21102344
Clin Psychol Rev. 2007 Jun;27(5):572-81
pubmed: 17343963
Int J Methods Psychiatr Res. 2006;15(4):167-80
pubmed: 17266013
J Psychosom Res. 2007 Feb;62(2):189-95
pubmed: 17270577
Behav Cogn Psychother. 2017 Nov;45(6):647-660
pubmed: 28528592
JAMA Intern Med. 2018 Sep 1;178(9):1278-1280
pubmed: 30039169
Int J Methods Psychiatr Res. 2004;13(2):93-121
pubmed: 15297906
Psychol Med. 2005 Dec;35(12):1761-72
pubmed: 16300690
Trials. 2017 Mar 14;18(1):122
pubmed: 28288676
Depress Anxiety. 2008;25(1):72-90
pubmed: 17146763
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Mol Psychiatry. 2011 Dec;16(12):1234-46
pubmed: 20938433
Psychol Bull. 2005 Sep;131(5):785-95
pubmed: 16187860
Depress Anxiety. 2012 Jul;29(7):614-20
pubmed: 22495990
Am J Psychiatry. 2005 Jun;162(6):1179-87
pubmed: 15930067

Auteurs

Dan J Stein (DJ)

Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa. dan.stein@uct.ac.za.

Alan E Kazdin (AE)

Department of Psychology, Yale University, New Haven, CT, USA.

Ayelet Meron Ruscio (AM)

Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA.

Wai Tat Chiu (WT)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Nancy A Sampson (NA)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Hannah N Ziobrowski (HN)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Sergio Aguilar-Gaxiola (S)

Center for Reducing Health Disparities, UC Davis Health System, Sacramento, California, USA.

Ali Al-Hamzawi (A)

College of Medicine, Al-Qadisiya University, Diwaniya governorate, Al Diwaniyah, Iraq.

Jordi Alonso (J)

Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Pompeu Fabra University (UPF), Barcelona, Spain.

Yasmin Altwaijri (Y)

Epidemiology Section, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Ronny Bruffaerts (R)

Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium.

Brendan Bunting (B)

School of Psychology, Ulster University, Londonderry, UK.

Giovanni de Girolamo (G)

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Peter de Jonge (P)

Department of Developmental Psychology, University of Groningen, Groningen, Netherlands.
Interdisciplinary Center Psychopathology and Emotion Regulation, University Medical Center Groningen, Groningen, Netherlands.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.

Oye Gureje (O)

Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

Josep Maria Haro (JM)

Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Meredith G Harris (MG)

School of Public Health, The University of Queensland, Herston, QLD, 4006, Australia.
Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, QLD, 4072, Australia.

Aimee Karam (A)

Institute for Development, Research, Advocacy & Applied Care (IDRAAC), Beirut, Lebanon.

Elie G Karam (EG)

Institute for Development, Research, Advocacy & Applied Care (IDRAAC), Beirut, Lebanon.
Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon.
Faculty of Medicine, Balamand University, Beirut, Lebanon.

Viviane Kovess-Masfety (V)

Ecole des Hautes Etudes en Santé Publique (EHESP), EA 4057, Paris Descartes University, Paris, France.

Sing Lee (S)

Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.

Maria Elena Medina-Mora (ME)

National Institute of Psychiatry-Ramón de la Fuente Muñiz, Mexico City, Mexico.

Jacek Moskalewicz (J)

Institute of Psychiatry and Neurology, Warsaw, Poland.

Fernando Navarro-Mateu (F)

UDIF-SM, Servicio Murciano de Salud; IMIB-Arrixaca; CIBERESP-Murcia, Región de Murcia, Murcia, Spain.

Daisuke Nishi (D)

Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
National Center of Neurology and Psychiatry, Tokyo, Japan.

José Posada-Villa (J)

Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia.

Kate M Scott (KM)

Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand.

Maria Carmen Viana (MC)

Department of Social Medicine, Postgraduate Program in Public Health, Federal University of Espírito Santo, Vitoria, Brazil.

Daniel V Vigo (DV)

Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Miguel Xavier (M)

Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School-Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.

Zahari Zarkov (Z)

Department of Mental Health, National Center of Public Health and Analyses, Sofia, Bulgaria.

Ronald C Kessler (RC)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH